To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse

NCT07730619 | Active Not Recruiting

• 1 other identifier: XJTU1AF2024LSYY-171
• Study Type: observational
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

In recent years, an increasing number of patients who have experienced poor efficacy or adverse drug reactions using traditional treatment regimens have received biologic therapy and achieved satisfactory treatment results. However, we also found that some patients have poor reactions to biological agents. Biological agents are often the final treatment choice for most patients, and patients often have high expectations for this treatment plan. Therefore, exploring the factors that affect the efficacy of biological agents and effective follow-up treatment plans when there is poor response to biological agents is of great significance for the treatment of psoriasis patients. The main research objective of this project is to observe and record the clinical characteristics and efficacy of plaque psoriasis patients treated with biological agents in the real world. 2. Explore the influencing factors of recurrence in plaque psoriasis patients receiving biological therapy in the real world, in order to increase awareness and awareness of this phenomenon, and provide guidance for preventing recurrence after biological therapy. 3. Record the follow-up treatment plans or response measures for recurrent patients, and compare the efficacy of different treatment plans. This study is a case-control study that recruited patients with plaque psoriasis who have received biological therapy for more than half a year. A questionnaire survey was conducted to understand their general information, disease-related clinical data, and laboratory examination data. Univariate analysis was used to compare all variables between groups, and logistic regression analysis was performed on variables with statistical differences. Corresponding ROC curves were then drawn. Perform a separate analysis of the Adalimumab group according to the above steps. In addition, descriptive analysis was conducted on the characteristics that may be related to the disease in the recurrence group, and the efficacy of different treatment plans after recurrence was compared.

Conditions

Plaque Psoriasis; Biologic Agents; Relapse; Influence Factors

Outcome Measures

Primary Outcomes (2)

• General Information

  Age, gender, occupation, education, height, weight, abdominal circumference, history of smoking or excessive drinking, dietary preferences, sleep quality, exercise status

  12/1/2022-12/1/2024

• Psoriasis related information

  The duration of illness, the name and administration scheme of the biological agent, the age when using the biological agent, the age of the first onset of psoriasis, the body surface involved area (BSA) of the skin lesions when injecting the first dose of biological agent, whether to comply with medical advice, whether to have psoriasis comorbidity, whether to treat other diseases at the same time, whether to have a family history of psoriasis, whether to involve joints, whether to involve special parts, whether to have infectious diseases during the treatment period, whether to vaccinate COVID-19 vaccine

  12/1/2022-12/1/2024

Secondary Outcomes (2)

• Laboratory testing indicators

  12/1/2022-12/1/2024

• Imaging examination

  12/1/2022-12/1/2024

Study Arms (2)

Recurrent group

Recurrence after biological therapy

Diagnostic Test: Diagnosis and Physical Examination of Psoriasis

Control group

No recurrence after treatment with biological agents

Diagnostic Test: Diagnosis and Physical Examination of Psoriasis

Interventions

Diagnosis and Physical Examination of Psoriasis DIAGNOSTIC_TEST

This study divided patients with plaque psoriasis treated with biological agents into a recurrent group and a non recurrent group based on whether they recurred or not

Control group; Recurrent group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study retrospectively selected plaque psoriasis patients who received biologic treatment in the dermatology department of our hospital from December 2022 to December 2024.

You may qualify if:

• Diagnosed as plaque psoriasis.
• Received biological therapy for more than six months.
• Voluntarily participate in this study, with normal communication and understanding abilities.
• Recurrent group: Patients with initial treatment effective (PGA or BSA improvement reduced by more than 75% from baseline), PGA ≥ 3 or BSA decreased by less than 50% from baseline after a period of time \[218\], and who were treated in the dermatology department of our hospital.
• Control group: Treatment effective (PGA maintained at 0/1 or BSA improvement decreased by more than 75% from baseline), and no recurrence as mentioned in ④ occurred.

You may not qualify if:

• Patients with other types of psoriasis.
• Pregnant patients
• Patients who refuse to cooperate with medical staff questionnaire surveys or refuse to provide auxiliary testing or examination materials.

Sponsors & Collaborators

• First Affiliated Hospital Xi'an Jiaotong University: lead

Study Sites (1)

Dermatology Department of the First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China

Location

MeSH Terms

Conditions

Recurrence

Interventions

Diagnosis

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 16, 2026
• First Posted: July 28, 2026
• Study Start: December 1, 2022
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: July 28, 2026

Record last verified: 2026-07

Locations

CN (1)